Adma Biologics (ADMA) Non-Current Debt (2012 - 2025)

Adma Biologics has reported Non-Current Debt for 13 years, with the latest figure at $69.3 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt fell 4.16% year-over-year to $69.3 million; the trailing twelve-month figure through Dec 2025 stood at $69.3 million (down 4.16% YoY), and the FY2025 full-year result was $69.3 million, down 4.16% from the prior year.
• Non-Current Debt for Q4 2025 stood at $69.3 million, down from $70.1 million in the prior quarter.
• The five-year high for Non-Current Debt was $144.3 million in Q1 2023, with the low at $69.3 million in Q4 2025.
• Historically, Non-Current Debt has averaged $110.9 million across 5 years, with a median of $116.0 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Debt soared 526.22% — and 2024, when it slumped 44.61%.
• Adma Biologics' Non-Current Debt stood at $94.9 million in 2021, then jumped by 50.56% to $142.8 million in 2022, then declined by 8.57% to $130.6 million in 2023, then tumbled by 44.61% to $72.3 million in 2024, then fell by 4.16% to $69.3 million in 2025.
• The last three Non-Current Debt figures came in at $69.3 million (Q4 2025), $70.1 million (Q3 2025), and $73.4 million (Q2 2025), per Business Quant data.